Your browser doesn't support javascript.
loading
Fabrication of PEGylated SPIONs-Loaded Niosome for Codelivery of Paclitaxel and Trastuzumab for Breast Cancer Treatment: In Vivo Study.
Masoumi Godgaz, Saeideh; Asefnejad, Azadeh; Bahrami, S Hajir.
Affiliation
  • Masoumi Godgaz S; Department of Biomedical Engineering, Science and Research Branch, Islamic Azad University, Tehran 1477893855,Iran.
  • Asefnejad A; Department of Biomedical Engineering, Science and Research Branch, Islamic Azad University, Tehran 1477893855,Iran.
  • Bahrami SH; Department of Textile Engineering, Amirkabir University of Technology, Tehran15875-4413,Iran.
ACS Appl Bio Mater ; 7(5): 2951-2965, 2024 05 20.
Article in En | MEDLINE | ID: mdl-38602218
ABSTRACT
There is a growing appeal for engineering drug delivery systems for controlled and local drug delivery. Conjugation of antibodies on the nanocarriers for targeted chemotherapeutic drugs has always been one of the main techniques. This work aims to develop a polycaprolactone/chitosan electrospun mat incorporated with paclitaxel/Fe3O4-loaded niosomes (SPNs) decorated with trastuzumab (TbNs) for cancer therapy. SPNs and TbNs were analyzed by DLS, zeta potential, scanning electron microscopy, transmission electron microscopy, and Fourier transform infrared spectroscopy. Fabricated mats with distinct concentrations of TbNs were classified into four groups (G0 (0), G1 (1), G2 (2.5), and G3 (5%)) and were studied physicochemically, mechanically, and biologically. Paclitaxel release was also studied for 7 days under an alternative magnetic field (AMF). The optimized mat was nominated for an in vivo study to evaluate its tumor growth inhibition. Based on the results, the TbNs had a spherical core and shell morphology with a smooth surface. The zeta potential and the mean size of TbNs were equal to -14.7 mV and 221 nm. TbNs did not affect the morphology and quality of nanofibers, but in general, the presence of TbNs increased the elastic modulus, water uptake, and degradation. Regarding the release study, AMF showed a significant increase in accelerating paclitaxel release from mats, and most releases belonged to the mat with 5% of TbNs. Results from the in vivo study showed the effective and synergistic effects of AMF on drug release and significant tumor growth inhibition. To summarize, the proposed nanocarrier under AMF can be a good candidate for cancer therapy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Particle Size / Breast Neoplasms / Paclitaxel / Trastuzumab Limits: Animals / Female / Humans Language: En Journal: ACS Appl Bio Mater Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Particle Size / Breast Neoplasms / Paclitaxel / Trastuzumab Limits: Animals / Female / Humans Language: En Journal: ACS Appl Bio Mater Year: 2024 Document type: Article Affiliation country: Country of publication: